JP5453096B2 - （−）−δ９−トランス−テトラヒドロカンナビノールを含んでなる組成物 - Google Patents

（−）−δ９−トランス−テトラヒドロカンナビノールを含んでなる組成物 Download PDF

Info

Publication number
JP5453096B2
JP5453096B2 JP2009535748A JP2009535748A JP5453096B2 JP 5453096 B2 JP5453096 B2 JP 5453096B2 JP 2009535748 A JP2009535748 A JP 2009535748A JP 2009535748 A JP2009535748 A JP 2009535748A JP 5453096 B2 JP5453096 B2 JP 5453096B2
Authority
JP
Japan
Prior art keywords
acid
composition
tetrahydrocannabinol
solvent
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009535748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509292A5 (enExample
JP2010509292A (ja
Inventor
ロナルド、ロッシ
リー、ジョナサン、シルバーバーグ
ロバート、ホーガン
ラメシュ、シャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey PLC
Original Assignee
Johnson Matthey PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey PLC filed Critical Johnson Matthey PLC
Publication of JP2010509292A publication Critical patent/JP2010509292A/ja
Publication of JP2010509292A5 publication Critical patent/JP2010509292A5/ja
Application granted granted Critical
Publication of JP5453096B2 publication Critical patent/JP5453096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2009535748A 2006-11-10 2007-11-09 （−）−δ９−トランス−テトラヒドロカンナビノールを含んでなる組成物 Active JP5453096B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/595,682 2006-11-10
US11/595,682 US8039509B2 (en) 2006-11-10 2006-11-10 Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
PCT/EP2007/062174 WO2008055992A1 (en) 2006-11-10 2007-11-09 Composition comprising (-)-δ9-trans-tetrahydrocannabinol

Publications (3)

Publication Number Publication Date
JP2010509292A JP2010509292A (ja) 2010-03-25
JP2010509292A5 JP2010509292A5 (enExample) 2010-12-24
JP5453096B2 true JP5453096B2 (ja) 2014-03-26

Family

ID=39149274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535748A Active JP5453096B2 (ja) 2006-11-10 2007-11-09 （−）−δ９−トランス−テトラヒドロカンナビノールを含んでなる組成物

Country Status (9)

Country Link
US (4) US8039509B2 (enExample)
EP (1) EP2086954B1 (enExample)
JP (1) JP5453096B2 (enExample)
CN (1) CN101578276A (enExample)
AU (1) AU2007316584B2 (enExample)
CA (1) CA2669021A1 (enExample)
IL (1) IL198651A (enExample)
MX (1) MX2009005003A (enExample)
WO (1) WO2008055992A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
EP2642982A2 (en) * 2010-11-22 2013-10-02 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
DE102012105063C5 (de) * 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
USD772284S1 (en) * 2014-09-01 2016-11-22 Apple Inc. Display screen or portion thereof with a set of graphical user interfaces
JP6676062B2 (ja) 2014-11-03 2020-04-08 ラモト アト テルーアビブ ユニバーシティー リミテッド 認知低下を処置するための方法
USD776682S1 (en) * 2015-09-04 2017-01-17 Salesforce.Com, Inc. Display screen or portion thereof with animated graphical user interface
USD801377S1 (en) * 2015-09-28 2017-10-31 ProductionPro LLC Display panel with transitional graphical user interface
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
CA3072768C (en) 2017-08-27 2024-06-11 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
CA3173494A1 (en) * 2020-09-24 2022-03-31 Michael Foster DAVIS Cannabinoid composition comprising at least 50% carrier

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
WO2003006010A1 (en) 2001-07-10 2003-01-23 Norton Healthcare Limited Aerosol formulations of δ8 tetrahydrocannabinol
WO2004000290A1 (en) 2002-06-22 2003-12-31 Norton Healthcare Limited Pharmaceutical composition
PT1542657E (pt) 2002-08-14 2012-02-29 Gw Pharma Ltd Formulações líquidas canabinóides para administração pela mucosa
US20040229939A1 (en) * 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
GB0329635D0 (en) 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
AU2005314021B2 (en) 2004-12-09 2010-02-11 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
ZA200802767B (en) * 2005-09-29 2009-09-30 Amr Technology Inc Process for production of delta-9-tetrahydrocannabinol
EP2046290A4 (en) 2006-08-04 2011-08-17 Insys Therapeutics Inc AQUEOUS DRONABINOL FORMULATIONS
EP1927582A1 (en) 2006-11-07 2008-06-04 Cytec Surface Specialties, S.A. Coatings for ceramic substrates
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
WO2009020666A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment

Also Published As

Publication number Publication date
US20120010279A1 (en) 2012-01-12
EP2086954A1 (en) 2009-08-12
US20130345299A1 (en) 2013-12-26
US8476312B2 (en) 2013-07-02
US20120322866A1 (en) 2012-12-20
US8039509B2 (en) 2011-10-18
AU2007316584A1 (en) 2008-05-15
AU2007316584B2 (en) 2013-02-14
CN101578276A (zh) 2009-11-11
MX2009005003A (es) 2009-06-12
US8906956B2 (en) 2014-12-09
WO2008055992A1 (en) 2008-05-15
JP2010509292A (ja) 2010-03-25
IL198651A0 (en) 2010-02-17
US20080139644A1 (en) 2008-06-12
IL198651A (en) 2014-09-30
CA2669021A1 (en) 2008-05-15
EP2086954B1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
JP2010509292A (ja) （−）−δ９−トランス−テトラヒドロカンナビノールを含んでなる組成物
US9814775B2 (en) Method for making and storing stable cannabinoid compositions and method for treatment using such compositions
JP3617055B2 (ja) ４，５―エポキシモルヒナン誘導体を含有する安定な医薬品組成物
EP1117440B1 (en) Pharmaceutical compositions containing paclitaxel
RU2621615C2 (ru) Фармацевтическая композиция, содержащая луликоназол
WO2012071389A2 (en) Stable cannabinoid compositions and methods for making and storing them
JP2005002123A5 (enExample)
JP6796638B2 (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
KR20220058086A (ko) 항진균제를 포함하는 안정화된 조성물
EP0651993A1 (en) Percutaneously administrable base composition and drug composition prepared therefrom
WO2014075554A1 (zh) 含有西罗莫司酯化物的药物组合物及其制备方法
US7699987B2 (en) Stabilized formulation
EP2389931A1 (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
HK1137444A (en) Composition comprising (-)-△9-trans-tetrahydrocannabinol
JP5897299B2 (ja) ローション剤
KR100389671B1 (ko) 염산 테르비나핀을 함유하는 항진균제 외용 약제 조성물
EP4444272B1 (en) A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity
TWI907378B (zh) 含有雷帕黴素的外用劑及其製造方法
KR100312177B1 (ko) 안정성이 개선된 파크리탁셀 주사제 조성물 및 그의 제조방법
KR20110111112A (ko) 테르비나핀 염산염의 안정성을 향상시키는 방법
WO2018163202A1 (en) Stable dronabinol formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140106

R150 Certificate of patent or registration of utility model

Ref document number: 5453096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250